Resignation

July 03, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Dear Sir/Madam, Subject: Outcome of Board Meeting held on Friday, July 03, 2026 Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, at its meeting held today, i.e., Friday, July 03, 2026, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with the deemed venue being the Registered Office of the Company inter-alia has considered and approved the: 1. Appointment of Mr. Santosh Parab (DIN:01622988) as an Additional Director in the capacity of Non-Executive Non-Independent Director w.e.f. July 03, 2026. The brief profile of the same is annexed as “Annexure -1”. 2. Appointment of Mr. Rahul Adakmol as Chief Executive Officer of the Company with effect from July 15, 2026. The brief profile of the same is annexed as “Annexure -2”. 3. Mr. Narsimha Shibroor Kamath has stepped aside from the position of Chief Executive Officer with effect from close of business hours on July 14, 2026, while continuing to serve as the Managing Director of the Company. The brief details along with the resignation letter are annexed as “Annexure 3”. Details as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, read with Master Circular No. SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762 /2026 dated January 30, 2026, as annexed. The Board of Directors' meeting concluded at 04:07 p.m. Kindly take the above information on record. Thanking you. Yours faithfully, For Bliss GVS Pharma Limited Aditi Bhatt Company Secretary Encl.: As above ‘Annexure-1’ Particulars Details of Particulars Name Mr. Santosh Parab Reason for change viz. Appointment appointment, re- Appointment of Mr. Santosh Parab (DIN: 01622988) as an appointment, resignation, Additional Director in the capacity of Non-Executive removal, death or Director of the Company. otherwise Designation Additional Director (Non-Executive - Non-Independent) Date of appointment / July 03, 2026 cessation & Term of appointment Brief Profile Mr. Santosh Parab is a qualified Chartered Accountant with over 35 years of experience in audit, taxation, corporate finance, valuation, mergers and acquisitions, restructuring, and financial management. Throughout his career, he has led audit, tax, regulatory, and advisory assignments for leading banks, financial institutions, insurance companies, and manufacturing organizations. He possesses extensive expertise in business valuations, due diligence, financial restructuring, and corporate advisory services. Having worked with several reputed organizations, including State Bank of India, ICICI Bank, Kotak Mahindra Bank, and Bliss GVS Pharma Limited, Mr. Parab brings deep financial expertise, strategic insight, and strong governance experience to the Company. Disclosure Nil of relationships between directors ‘Annexure-2’ Particulars Details of Particulars Name Mr. Rahul Adakmol Reason for change viz. Appointment appointment, re- Appointment of Mr Rahul Adakmol as the Chief Executive appointment, resignation, Officer of the Company removal, death or otherwise Designation Chief Executive Officer Date July 15, 2026 of appointment/cessation & Term of appointment Brief Profile Mr. Rahul Adakmol, is Bachelor of Chemical Engineering from UDCT, Mumbai and MBA from the Indian Institute of Management (IIM), Bangalore. He is an experienced CXO with over 22 years of experience deep expertise across value chain including Sales, Marketing, Manufacturing, Supply Chain, Medico-Regulatory, Strategy, Portfolio while leading International Operations, Subsidiaries, Manufacturing and R&D. He has successfully built and scaled high-growth specialty businesses, led strategic acquisitions, licensing initiatives, and global market expansion across 70+ countries. He has held senior leadership positions at Bharat Serums and Vaccines, Dr. Reddy’s Laboratories, and Reliance Industries, consistently driving profitable growth, organizational transformation, and value creation. He is recognized for his strategic vision and leadership excellence. Disclosure Nil of relationships between directors ‘Annexure -3’ Particulars Details of Particulars Name Mr. Narsimha Shibroor Kamath Reason for change viz. Resignation appointment, re- Resignation of Mr Narsimha Shibroor Kamath from the appointment, position of Chief Executive Officer w.e.f. close of business resignation, removal, hours on July 14, 2026, while continuing to serve as the death or otherwise Managing Director of the Company. Designation Not Applicable Date With effect from the close of business hours of July 14, 2026 of appointment/cessation & Term of appointment Brief Profile Not Applicable Disclosure Nil of relationships between directors